High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 49, 2015, Pages 15196-15201

  Klumpp, Klaus ^a   Lam, Angela M ^a   Lukacs, Christine ^b   Vogel, Robert ^a   Ren, Suping ^a   Espiritu, Christine ^a   Baydo, Ruth ^b   Atkins, Kateri ^b   Abendroth, Jan ^b   Liao, Guochun ^c   Efimov, Andrey ^d   Hartman, George ^a   Flores, Osvaldo A ^a  

^a Novira Therapeutics   (United States)

^b Beryllium   (United States)

^c Vista Informatics Corporation   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Capsid; Core; HBV inhibitor; HBV treatment; Proteinprotein interaction

Indexed keywords

ALANINE; ANTIVIRUS AGENT; BAY 414109; CORE PROTEIN; DIMER; GSL 4; MUTANT PROTEIN; NVR 010001 E2; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; DRUG POTENCY; DRUG PROTEIN BINDING; GENE MUTATION; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THERMOSTABILITY; VIRUS ASSEMBLY; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; HEPATITIS B VIRUS; PROTEIN CONFORMATION; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 84949236288     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1513803112     Document Type: Article

References (24)

1. Cowie BC, Carville KS, MacLachlan JH (2013) Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: New evidence of an urgent global public health priority demanding action. Antivir Ther 18(8):953-954.
2. Klumpp K, Crépin T (2014) Capsid proteins of enveloped viruses as antiviral drug targets. Curr Opin Virol 5:63-71.
3. Seeger C, Zoulim F, Mason WS (2013) Hepadnaviruses. Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), Vol II, pp 2185-2221.
4. Dryden KA, et al. (2006) Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell 22(6):843-850.
5. Wynne SA, Crowther RA, Leslie AG (1999) The crystal structure of the human hepatitis B virus capsid. Mol Cell 3(6):771-780.
6. Bourne C, et al. (2008) Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol 82(20):10262-10270.
7. Campagna MR, et al. (2013) Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87(12):6931-6942.
8. Cho MH, Jeong H, Kim YS, Kim JW, Jung G (2014) 2-amino-N-(2, 6-dichloropyridin-3-yl) acetamide derivatives as a novel class of HBV capsid assembly inhibitor. J Viral Hepat 21(12):843-852.
9. Deres K, et al. (2003) Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299(5608):893-896.
10. Feld JJ, et al. (2007) The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 76(2):168-177.
11. Wang XY, et al. (2012) In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 17(5):793-803.
12. Brezillon N, et al. (2011) Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 6(12):e25096.
13. Weber O, et al. (2002) Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 54(2):69-78.
14. Wu G, et al. (2013) Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother 57(11):5344-5354.
15. Bourne CR, Finn MG, Zlotnick A (2006) Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 80(22):11055-11061.
16. Katen SP, Tan Z, Chirapu SR, Finn MG, Zlotnick A (2013) Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure 21(8):1406-1416.
17. Bourne CR, Katen SP, Fulz MR, Packianathan C, Zlotnick A (2009) A mutant hepatitis B virus core protein mimics inhibitors of icosahedral capsid self-assembly. Biochemistry 48(8):1736-1742.
18. Packianathan C, Katen SP, Dann CE, 3rd, Zlotnick A (2010) Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly. J Virol 84(3):1607-1615.
19. Alexander CG, et al. (2013) Thermodynamic origins of protein folding, allostery, and capsid formation in the human hepatitis B virus core protein. Proc Natl Acad Sci USA 110(30):E2782-E2791.
20. Gane EJ, et al. (2014) Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor. Hepatology 60:1279A.
21. Böttcher B, Vogel M, Ploss M, Nassal M (2006) High plasticity of the hepatitis B virus capsid revealed by conformational stress. J Mol Biol 356(3):812-822.
22. Zlotnick A, et al. (2007) In vitro screening for molecules that affect virus capsid assembly (and other protein association reactions). Nat Protoc 2(3):490-498.
23. Zlotnick A, Ceres P, Singh S, Johnson JM (2002) A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J Virol 76(10):4848-4854.
24. Zhang JM, et al. (2005) High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations. J Med Virol 77(2):203-208.